MX2024011697A - Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3) - Google Patents

Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)

Info

Publication number
MX2024011697A
MX2024011697A MX2024011697A MX2024011697A MX2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A MX 2024011697 A MX2024011697 A MX 2024011697A
Authority
MX
Mexico
Prior art keywords
domain
nlrp3
pyrido
nucleotide
receptor
Prior art date
Application number
MX2024011697A
Other languages
English (en)
Spanish (es)
Inventor
Stéphane Dorich
Amandine Chefson
Stéphane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of MX2024011697A publication Critical patent/MX2024011697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2024011697A 2022-03-25 2024-09-24 Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3) MX2024011697A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US202263420930P 2022-10-31 2022-10-31
US202363443874P 2023-02-07 2023-02-07
PCT/US2023/064967 WO2023183943A1 (en) 2022-03-25 2023-03-24 Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives

Publications (1)

Publication Number Publication Date
MX2024011697A true MX2024011697A (es) 2024-11-08

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011697A MX2024011697A (es) 2022-03-25 2024-09-24 Derivados de pirido-[3,4-d]piridazina amina utiles como derivados de proteinas que contienen el dominio de pirina de la familia de los receptores similares al dominio de oligomerizacion de union a nucleotido 3 (nlrp3)

Country Status (13)

Country Link
EP (1) EP4499638A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510414A (cg-RX-API-DMAC7.html)
KR (1) KR20250005125A (cg-RX-API-DMAC7.html)
CN (1) CN119137121A (cg-RX-API-DMAC7.html)
AU (1) AU2023238121A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246681A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002855A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013702A2 (cg-RX-API-DMAC7.html)
IL (1) IL315842A (cg-RX-API-DMAC7.html)
MX (1) MX2024011697A (cg-RX-API-DMAC7.html)
PE (1) PE20250605A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345836A (cg-RX-API-DMAC7.html)
WO (1) WO2023183943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
WO2025059481A1 (en) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors

Also Published As

Publication number Publication date
AU2023238121A1 (en) 2024-10-10
IL315842A (en) 2024-11-01
CN119137121A (zh) 2024-12-13
CO2024013702A2 (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
EP4499638A1 (en) 2025-02-05
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CL2024002855A1 (es) 2025-02-14
CA3246681A1 (en) 2023-09-28
PE20250605A1 (es) 2025-02-26
WO2023183943A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CL2024002855A1 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3.
CO2024001367A2 (es) Compuestos antivirales
CR20250413A (es) Compuestos de pirido[4,3–d]pirimidina
BR112023021383A2 (pt) Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
AR066972A1 (es) Derivados azapeptidicos
AR087301A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
PE20220705A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer
AR076949A1 (es) Derivados de 1h-imidazo-(4,5-c)-quinolinona
CO2024015371A2 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos
CL2021002575A1 (es) Compuestos de pirrol
AR126537A1 (es) Sales y formas en estado sólido de un compuesto inhibidor de kif18a
UY39799A (es) Compuestos de pirrolil–sulfonamida
CL2024001620A1 (es) Inhibidores del sarcómero cardíaco
CL2021003139A1 (es) Compuestos tricíclicos
MX2024011179A (es) Compuestos multiciclicos
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
DOP2024000146A (es) Inhibidores de parp7
CL2025001819A1 (es) Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
AR133250A1 (es) Nuevos compuestos
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales
CO2025004701A2 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.